Immunohistochemical analysis of CBFβ-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22)

American Journal of Surgical Pathology

Volumn 30, Issue 11, 2006, Pages 1436-1444

  Zhao, Weiqiang ^a   Claxton, David F ^a   Jeffrey Medeiros, L ^a   Lu, Di ^a   Vadhan Raj, Saroj ^a   Kantarjian, Hagop M ^b   Nguyen, Martin H ^a   Bueso Ramos, Carlos E ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; CBF ; Immunofluorescence; Immunohistochemistry; inv(16)(p13q22); M4Eo; MYH11; SMMHC; t(16; 16)(p13; q22)

Indexed keywords

CHIMERIC PROTEIN; CORE BINDING FACTOR; HYBRID PROTEIN; MYOSIN; POLYCLONAL ANTIBODY; SMOOTH MUSCLE MYOSIN HEAVY CHAIN; UNCLASSIFIED DRUG; CBFB PROTEIN, HUMAN; CORE BINDING FACTOR BETA; MYOSIN HEAVY CHAIN; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CELL MEMBRANE; CHROMOSOME 16; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; NUCLEAR LOCALIZATION SIGNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; CELL NUCLEUS; CHROMOSOME INVERSION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MYELOMONOCYTIC LEUKEMIA; SENSITIVITY AND SPECIFICITY; TIME;

ADOLESCENT; ADULT; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 16; CORE BINDING FACTOR BETA SUBUNIT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; INVERSION, CHROMOSOME; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; MYOSIN HEAVY CHAINS; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33750491125     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000213301.19273.66     Document Type: Article

References (33)

1. Admirand JH, Rassidakis GZ, Abruzzo LV, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol. 2004;17:954-961.
2. Adya N, Stacy T, Speck NA, et al. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol. 1998;18:7432-7443.
3. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. Blood. 1983;61:994-998.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
5. Bitter MA, Le Beau MM, Larson RA, et al. A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). Am J Clin Pathol. 1984;81:733-741.
6. Brunning RD, Matutes E, Flandrin G, et al. Acute myeloid leukemia with recurrent cytogenetic abnormalities. In: Jaffe ES, Harris NL, Stein H, eds. Pathology and Genetics of tumours of Haematopoietic and lymphoid Tissues. Lyon, France: Classification of Tumours; 2001:82-84.
7. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780-786.
8. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83:1750-1756.
9. Claxton D, Xie QS, Patel S, et al. The gene product of CBFB-MYH11. Leukemia. 1996;10:1479-1485.
10. Haferlach T, Winkemann M, Loffler H, et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization. Blood. 1996;87:2459-2463.
11. Huang G, Shigesada K, Wee HJ, et al. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood. 2004;103:3200-3207.
12. Kanno Y, Kanno T, Sakakura C, et al. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol. 1998;18:4252-4261.
13. Kundu M, Chen A, Anderson S, et al. Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. Blood. 2002;100:2449-2456.
14. Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
15. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983;309:630-636.
16. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85:2289-2302.
17. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044.
18. Liu PP, Wijmenga C, Hajra A, et al. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosomes Cancer. 1996;16:77-87.
19. Lu J, Maruyama M, Satake M, et al. Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF. Mol Cell Biol. 1995;15:1651-1661.
20. Lukasik SM, Zhang L, Corpora T, et al. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. Nat Struct Biol. 2002;9:674-679.
21. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18:768-780.
22. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood. 1995;85:772-779.
23. Merzianu M, Medeiros LJ, Cortes J, et al. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005;124:807-814.
24. Nakamura H, Sadamori N, Tagawa M, et al. Inversion of chromosome 16 in bone marrow eosinophils of acute myelomonocytic leukemia (M4) with eosinophilia. Cancer Genet Cytogenet. 1987;29:327-330.
25. Poirel H, Radford-Weiss I, Rack K, et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood. 1995;85:1313-1322.
26. Reilly JT. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? Br J Haematol. 2005;128:18-34.
27. Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004;23:4297-4307.
28. Simons M, Wang M, McBride OW, et al. Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes. Circ Res. 1991;69:530-539.
29. Sun X, Medeiros LJ, Lu D, et al. Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). Am J Clin Pathol. 2003;120:236-245.
30. Villamor N, Costa D, Aymerich M, et al. Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. Am J Clin Pathol. 2000;114:786-792.
31. Viswanatha DS, Chen I, Liu PP, et al. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)- associated acute myeloid leukemias. Blood. 1998;91:1882-1890.
32. Yanagisawa K, Fukuoka T, Fujita S. Evidence for the neoplastic involvement of monocytic, eosinophilic and basophilic lineages in acute myelomonocytic leukemia with eosinophilia. Acta Haematol. 1990;83:145-148.
33. Yanagisawa K, Horiuchi T, Fujita S. Establishment and characterization of a new human leukemia cell line derived from M4E0. Blood. 1991;78:451-457.